These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 27656858)

  • 21. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
    Ferrandiz-Pulido C; Garcia-Patos V
    Arch Dis Child; 2013 Dec; 98(12):998-1003. PubMed ID: 23873883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fatal toxic epidermal necrolysis associated with minoxidil.
    Karaoui LR; Chahine-Chakhtoura C
    Pharmacotherapy; 2009 Apr; 29(4):460-7. PubMed ID: 19323621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Liotti L; Caimmi S; Bottau P; Bernardini R; Cardinale F; Saretta F; Mori F; Crisafulli G; Franceschini F; Caffarelli C
    Acta Biomed; 2019 Jan; 90(3-S):52-60. PubMed ID: 30830062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review.
    Yager JA
    Vet Dermatol; 2014 Oct; 25(5):406-e64. PubMed ID: 24990284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tohyama M; Watanabe H; Murakami S; Shirakata Y; Sayama K; Iijima M; Hashimoto K
    Br J Dermatol; 2012 Feb; 166(2):322-30. PubMed ID: 21936856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?
    Garcia-Doval I; LeCleach L; Bocquet H; Otero XL; Roujeau JC
    Arch Dermatol; 2000 Mar; 136(3):323-7. PubMed ID: 10724193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role?
    Mawson AR; Eriator I; Karre S
    Med Sci Monit; 2015 Jan; 21():133-43. PubMed ID: 25579087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levamisole induced toxic epidermal necrolysis: A case report.
    Rohilla R; Jain A
    Br J Clin Pharmacol; 2021 Mar; 87(3):1574-1577. PubMed ID: 32851655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Stevens-Johnson Syndrom and Toxic Epidermal Necrolysis--based on literature].
    Łoboda J; Dudzik A; Chomyszyn-Gajewska M
    Przegl Lek; 2015; 72(1):35-7. PubMed ID: 26076576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases.
    Lee HY; Tey HL; Pang SM; Thirumoorthy T
    Lupus; 2011 May; 20(6):647-52. PubMed ID: 21148602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acute life-threatening drug reactions of the skin].
    Mockenhaupt M
    Hautarzt; 2018 May; 69(5):364-375. PubMed ID: 29721625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding.
    French LE; Trent JT; Kerdel FA
    Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of toxic epidermal necrolysis management in Japan.
    Kinoshita Y; Saeki H
    Allergol Int; 2017 Jan; 66(1):36-41. PubMed ID: 27400826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases.
    Tremblay L; Pineton de Chambrun G; De Vroey B; Lavogiez C; Delaporte E; Colombel JF; Cortot A
    J Crohns Colitis; 2011 Oct; 5(5):457-60. PubMed ID: 21939920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
    Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
    Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
    Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
    Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents.
    Weinand C; Xu W; Perbix W; Lefering R; Maegele M; Rathert M; Spilker G
    Burns; 2013 Nov; 39(7):1449-55. PubMed ID: 23702222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Kaur-Knudsen D; Zachariae C; Thomsen SF
    Ugeskr Laeger; 2013 Dec; 175(50):3096-9. PubMed ID: 24629532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.